Partnering with MENDSHINE, Hotgen Biotech Accelerates In-Depth Channel Rollout of the Chinese Liver Health Project (CLHP)

Source: Hotgen Biotech
Date: 2026-11-16
Back to List

Recently, the signing ceremony for the strategic cooperation agreement between Hotgen Biotech and Jiangsu MENDSHINE Medical Technology Co., Ltd. (hereinafter "MENDSHINE") and the plaque-awarding ceremony for the Chinese Liver Health Project (CLHP) were held at MENDSHINE. Lin Changqing, Chairman and President of Hotgen Biotech, Ding Wanhe, Chairman of MENDSHINE, and team representatives from both sides attended the event, witnessing an important moment as the two parties deepened strategic cooperation and pursued shared development.

For Hotgen Biotech, the core logic of this cooperation lies not in channel distribution of individual products, but in systematically channeling the diagnostic product portfolio and technical capabilities accumulated through the Chinese Liver Health Project into a partner system that possesses in-depth regional service coverage and end-point operating capabilities.

The Chinese Liver Health Project (CLHP) is the core vehicle of Hotgen Biotech’s long-term commitment in liver disease diagnostics. Covering key links such as early screening for liver cancer, liver fibrosis assessment and detection of inflammation in metabolic dysfunction-associated fatty liver disease, Hotgen Biotech has built a distinctive diagnostic portfolio spanning the three-marker liver cancer panel (AFP, AFP-L3 and PIVKA-II), GP73, CK18 and HBV RNA, and continues to advance the clinical accessibility of digital-intelligence tools such as the C-GALAD liver cancer risk early-warning model. Realizing the value of this portfolio depends both on the sensitivity and specificity of the detection technologies themselves and on whether standardized, large-scale application can be achieved across a broader range of healthcare service settings.

87469520_1794796856.jpg

MENDSHINE has accumulated mature operating experience in serving medical institutions, integrating channel resources and managing supply chains. The end-user reach and professional service capabilities of its integrated operating platform are precisely the support Hotgen Biotech needs to extend the reach of its liver health management services. At the signing ceremony, both parties made clear that they will deepen collaboration in liver health management, health examinations and related laboratory testing, forging an efficient “product–service” linkage between Hotgen Biotech’s diagnostic portfolio and MENDSHINE’s channel and service network.

In his remarks, Chairman Lin Changqing said that Hotgen Biotech has always adhered to the philosophy of “Innovative Diagnostics, Value-based Testing”, and that liver health is one of the core strategic directions of the company’s diagnostics business. Cooperation with MENDSHINE is a key step in moving the Chinese Liver Health Project from building product capability to building service capability — enabling clinically validated diagnostic technologies, backed by a professional channel operating system, to enter frontline health management settings on a firmer footing.

From an industry perspective, competition in the IVD field is shifting from a contest over single-reagent performance to systematic capability competition built on “product portfolio + service network + end-point operations”. Hotgen Biotech’s product depth and technical accumulation in liver health diagnostics form the upstream foundation of the partnership, while MENDSHINE’s channel operations strengthen the downstream service delivery link. This “technology-driven + channel-deepening” collaborative structure builds a more resilient commercialization path for Hotgen Biotech in the liver health management arena.

Starting from this signing, Hotgen Biotech will continue to be guided by the Chinese Liver Health Project and to work with partners such as MENDSHINE to drive liver health management from a screening technology advantage toward large-scale health service effectiveness — validating product value through deeper channel penetration and realizing the clinical significance of diagnostic technologies through service delivery.

share